Pharmaceutical company Eli Lilly plans to acquire Morphic, a biopharmaceutical company that specializes in treating gastroenterology patients, for $3.2 billion.
Morphic's lead program is an oral treatment for inflammatory bowel disease patients, according to a July 8 news release.
The molecule is also being evaluated to treat patients with ulcerative colitis and Crohn's disease.
The transaction has been approved by the boards of directors of both com
Subscribe to the following topics: 1 pharmaceutical company2. eli lilly3. acquire4. morphic5. biopharmaceutical company6. gastroenterology patients7. inflammatory bowel disease8. $3.2 billion